Literature DB >> 6639091

[Treatment of multiple myeloma. High-dose intermittent administration of cyclophosphamide and prednisolone--follow up study of 10 years period].

H Mizuno, N Ninomiya, H Ohta, K Tokoro, A Yasuma, K Ohnishi, Y Ikeda.   

Abstract

Twenty patients with plasma cell myeloma were treated with high-dose (10 mg/kg) intermittent administration of cyclophosphamide for remission induction and maintenance therapy. High-dose intermittent administration of glucocorticosteroid hormone was also performed usually in parallel with large-dose of cyclophosphamide. A significant objective response was obtained in 12 of 20 patients (60.0%). The median survival was 32 months in all cases; 47 months in the responding cases. The response rate was not affected by the class of M-protein, the type of light-chain and/or the presence of bone lesions. All responders were on the 3rd stage. High-dose intermittent administration of cyclophosphamide was evaluated as very useful since it showed equivalent effects obtained by combination chemotherapy regimens, hardly producing bone marrow suppression.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6639091

Source DB:  PubMed          Journal:  Gan To Kagaku Ryoho        ISSN: 0385-0684


  1 in total

1.  Multi-drug combination therapy with vincristine-melphalan-cyclophosphamide-prednisolone was more effective than cyclophosphamide-prednisolone in stage III myeloma. The Nagoya Myeloma Cooperative Study Group.

Authors:  K Shimizu; O Kamiya; N Hamajima; H Mizuno; M Kobayashi; N Hirabayashi; H Takeyama; R Kato; K Kawashima; M Nitta
Journal:  Jpn J Cancer Res       Date:  1990-12
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.